Veriti Management LLC raised its holdings in shares of Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 5.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,632 shares of the medical research company's stock after purchasing an additional 743 shares during the quarter. Veriti Management LLC's holdings in Edwards Lifesciences were worth $1,486,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of EW. American National Bank increased its stake in Edwards Lifesciences by 99.1% during the 1st quarter. American National Bank now owns 233 shares of the medical research company's stock valued at $27,000 after purchasing an additional 116 shares in the last quarter. Core Alternative Capital grew its stake in shares of Edwards Lifesciences by 513.2% in the 1st quarter. Core Alternative Capital now owns 233 shares of the medical research company's stock worth $27,000 after acquiring an additional 195 shares in the last quarter. Rinkey Investments bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth $29,000. JJJ Advisors Inc. grew its stake in shares of Edwards Lifesciences by 79.1% in the 1st quarter. JJJ Advisors Inc. now owns 283 shares of the medical research company's stock worth $33,000 after acquiring an additional 125 shares in the last quarter. Finally, Gemmer Asset Management LLC bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth $36,000. Institutional investors own 81.33% of the company's stock.

Edwards Lifesciences Price Performance

NYSE EW opened at $84.74 on Monday. The company has a market cap of $52.53 billion, a PE ratio of 36.68, a price-to-earnings-growth ratio of 2.50 and a beta of 1.14. Edwards Lifesciences Co. has a 52 week low of $82.92 and a 52 week high of $131.73. The company has a quick ratio of 2.60, a current ratio of 3.37 and a debt-to-equity ratio of 0.10. The firm's 50-day simple moving average is $97.09 and its two-hundred day simple moving average is $101.65.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on EW shares. StockNews.com upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a research note on Wednesday, August 17th. Cowen reduced their target price on shares of Edwards Lifesciences from $140.00 to $125.00 in a research note on Monday, July 11th. Truist Financial reduced their target price on shares of Edwards Lifesciences from $117.00 to $112.00 and set a "buy" rating for the company in a research note on Thursday. Canaccord Genuity Group lowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating and reduced their target price for the stock from $115.00 to $106.00 in a research note on Friday, July 29th. Finally, Stifel Nicolaus cut their price target on shares of Edwards Lifesciences from $128.00 to $115.00 in a report on Monday, July 18th. Three analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of "Moderate Buy" and an average target price of $125.81.

Insider Transactions at Edwards Lifesciences

In other news, VP Bernard J. Zovighian sold 4,811 shares of the stock in a transaction dated Friday, August 5th. The shares were sold at an average price of $103.66, for a total value of $498,708.26. Following the sale, the vice president now directly owns 21,247 shares of the company's stock, valued at $2,202,464.02. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, VP Bernard J. Zovighian sold 4,811 shares of the stock in a transaction dated Friday, August 5th. The shares were sold at an average price of $103.66, for a total value of $498,708.26. Following the sale, the vice president now directly owns 21,247 shares of the company's stock, valued at $2,202,464.02. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Michael A. Mussallem sold 19,875 shares of the company's stock in a transaction that occurred on Thursday, July 14th. The stock was sold at an average price of $95.88, for a total transaction of $1,905,615.00. Following the completion of the transaction, the chief executive officer now owns 166,853 shares in the company, valued at $15,997,865.64. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 86,128 shares of company stock valued at $8,223,839. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

See Also

• Get a free copy of the StockNews.com research report on Edwards Lifesciences (EW)
• Can Caterpillar Claw Higher in a Falling Market?
• Is Dave & Buster's Immune to High Inflation and Lower Spending?
• Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
• Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
• MarketBeat: Week in Review 9/19 – 9/23

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW – Get Rating).

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.